872 related articles for article (PubMed ID: 28547076)
1. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
2. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
3. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.
Deaglio S; Robson SC
Adv Pharmacol; 2011; 61():301-32. PubMed ID: 21586363
[TBL] [Abstract][Full Text] [Related]
4. An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis.
Abron JD; Singh NP; Mishra MK; Price RL; Nagarkatti M; Nagarkatti PS; Singh UP
Am J Physiol Gastrointest Liver Physiol; 2018 Aug; 315(2):G220-G230. PubMed ID: 29672155
[TBL] [Abstract][Full Text] [Related]
5. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
6. Control of Gut Inflammation by Modulation of Purinergic Signaling.
Vuerich M; Mukherjee S; Robson SC; Longhi MS
Front Immunol; 2020; 11():1882. PubMed ID: 33072065
[TBL] [Abstract][Full Text] [Related]
7. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis.
Vuerich M; Harshe R; Frank LA; Mukherjee S; Gromova B; Csizmadia E; Nasser IAM; Ma Y; Bonder A; Patwardhan V; Robson SC; Longhi MS
J Hepatol; 2021 Jan; 74(1):48-57. PubMed ID: 32663496
[TBL] [Abstract][Full Text] [Related]
8. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
9. The Aryl Hydrocarbon Receptor (AHR) as a Potential Target for the Control of Intestinal Inflammation: Insights from an Immune and Bacteria Sensor Receptor.
Pernomian L; Duarte-Silva M; de Barros Cardoso CR
Clin Rev Allergy Immunol; 2020 Dec; 59(3):382-390. PubMed ID: 32279195
[TBL] [Abstract][Full Text] [Related]
10. Ectonucleotidases in Intestinal and Hepatic Inflammation.
Vuerich M; Robson SC; Longhi MS
Front Immunol; 2019; 10():507. PubMed ID: 30941139
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
12. Bilirubin suppresses Th17 immunity in colitis by upregulating CD39.
Longhi MS; Vuerich M; Kalbasi A; Kenison JE; Yeste A; Csizmadia E; Vaughn B; Feldbrugge L; Mitsuhashi S; Wegiel B; Otterbein L; Moss A; Quintana FJ; Robson SC
JCI Insight; 2017 May; 2(9):. PubMed ID: 28469075
[TBL] [Abstract][Full Text] [Related]
13. Purinergic Signaling as a Regulator of Th17 Cell Plasticity.
Fernández D; Flores-Santibáñez F; Neira J; Osorio-Barrios F; Tejón G; Nuñez S; Hidalgo Y; Fuenzalida MJ; Meza D; Ureta G; Lladser A; Pacheco R; Acuña-Castillo C; Guixé V; Quintana FJ; Bono MR; Rosemblatt M; Sauma D
PLoS One; 2016; 11(6):e0157889. PubMed ID: 27322617
[TBL] [Abstract][Full Text] [Related]
14. Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota.
Hou JJ; Ma AH; Qin YH
Front Cell Infect Microbiol; 2023; 13():1279172. PubMed ID: 37942478
[TBL] [Abstract][Full Text] [Related]
15. Purinergic dysregulation in pulmonary hypertension.
Visovatti SH; Hyman MC; Goonewardena SN; Anyanwu AC; Kanthi Y; Robichaud P; Wang J; Petrovic-Djergovic D; Rattan R; Burant CF; Pinsky DJ
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H286-98. PubMed ID: 27208163
[TBL] [Abstract][Full Text] [Related]
16. Decreased Frequency of Intestinal CD39
Libera J; Wittner M; Kantowski M; Woost R; Eberhard JM; de Heer J; Reher D; Huber S; Haag F; Schulze Zur Wiesch J
Front Immunol; 2020; 11():567472. PubMed ID: 33072107
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the T Cell Response by CD39.
Takenaka MC; Robson S; Quintana FJ
Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363
[TBL] [Abstract][Full Text] [Related]
18. Variable impact of CD39 in experimental murine colitis.
Künzli BM; Berberat PO; Dwyer K; Deaglio S; Csizmadia E; Cowan P; d'Apice A; Moore G; Enjyoji K; Friess H; Robson SC
Dig Dis Sci; 2011 May; 56(5):1393-403. PubMed ID: 20936356
[TBL] [Abstract][Full Text] [Related]
19. Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.
Lee JS; Yilmaz Ö
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315226
[TBL] [Abstract][Full Text] [Related]
20. Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.
Robles RJ; Mukherjee S; Vuerich M; Xie A; Harshe R; Cowan PJ; Csizmadia E; Wu Y; Moss AC; Chen R; Robson SC; Longhi MS
J Crohns Colitis; 2020 Jul; 14(6):818-830. PubMed ID: 31693091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
